Stepwise Strategy for Treatment of Atrial Fibrillation Substrate Extended Study

Condition(s) studied

Investigational drug(s) / intervention(s)

other: This study mainly describe the evolution and characteristic of patients with atrial fibrillation under different treatment plans and comorbidities.

Study summary

This is an observational, bidirectional cohort study, aiming to establish a long-term registry of adult patients with Persistent atrial fibrillation (ps-AF) in Southwest China to characterize patient profiles and evaluate embolism risk, rate control, rhythm control and complication management and outcomes over 5 years' follow-up. The objectives of the study are to: Describe the demographic, clinical, and treatment characteristics of ps-AF patients across Southwest China and assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, electrical cardioversion, catheter ablation, and left atrial appendage closure, in routine clinical practice. Identify patient- and treatment-related factors that influence therapeutic outcomes. Explore the characteristics of imaging multi-omics and blood multi-omics during follow-up. Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.

Eligibility

Primary outcome measure(s)

• Composite endpoint of stroke, major bleeding, worsening and new-onset heart failure, all-cause mortality — 5 years
  Composite endpoint of stroke, major bleeding, worsening heart failure, new-onset heart failure, and all-cause mortality
• Major bleeding events, perioperative complications and adverse drug reactions — 5 years
  Major bleeding events (e.g., intracranial hemorrhage, gastrointestinal bleeding); Perioperative complications (e.g., pericardial tamponade, thrombus formation, vascular complications); Adverse drug reactions (e.g., anticoagulant-induced thrombocytopenia, amiodarone-induced thyroid dysfunction, prolonged QT interval, bradyarrhythmia, pulmonary fibrosis, etc.).

Trial sites (1)

More Yuehui Yin trials in China

Other trials for the same condition